2017年 · 第40卷第12期

According to the spirit of the letter of the General Office of the Ministry of Health on entrusting the formulation of the index system of clinical laboratory quality management and control (Wei Ban Yi Zheng Han [2009] No.723), the grass-roots laboratory technology standardization branch of China Medical Care International Exchange Promotion Association organized relevant experts to formulate the expert consensus on the application of chemiluminescence system in grass-roots laboratories according to the requirements on clinical laboratory quality and management in the Guidelines for Accreditation of Medical Laboratories (the third revised edition in 2015), Hospital Management Evaluation Guidelines (Wei Yi Fa [2008] No.27), General Hospital Evaluation Standards (2009 edition), Patient Safety Goals (2010 edition) and the Administrative Measures for Clinical Laboratories in Medical Institutions (Wei Yi Fa [2006] No.73) of China Conformity Assessment and Accreditation Committee, and combined with China's basic national conditions, the expert consensus on the application of chemiluminescence system in grass-roots laboratories was formulated.

acute myeloid leukemia (AML) is a highly heterogeneous disease, and its incidence rate accounts for about 60% of adult acute leukemia. Although its pathogenesis often involves many forms of chromosomal changes, about 45% of newly diagnosed AML cannot detect chromosomal changes. nucleophosmin (NPM1) mutation is one of the most common gene mutations in AML^[1]； It is one of the main molecular events leading to leukemia^[2]； It is closely related to primary AML, but occasionally occurs in secondary AML^[3]； They are mostly distributed in other AML subtypes except M3, M4EO and M7, and mostly involve patients with normal chromosome karyotype, and are closely related to the occurrence and development of the disease^[2,4]Therefore, the study of NPMl mutation has important clinical significance for the diagnosis, treatment and prognosis of AML patients.

The concept of point of care testing (POCT) has been introduced into China from Europe and the United States for nearly 20 years. It is generally believed that POCT refers to the instant and on-the-spot detection method that uses portable small analytical instruments, is simple to operate, is applied near the patient, and can quickly get the detection results^[1]。 However, due to the huge differences between China's medical system and medical treatment methods and those in Europe and the United States, the positioning of POCT products has been controversial by people in the industry after entering the Chinese medical market. After years of joint exploration by manufacturers, inspectors and clinical practices, POCT in China has formed a large industry scale and market. From 2009 to 2014, the market size of China's POCT industry increased year by year. In 2009, the market size of POCT industry in China was USD 273 million, and by 2014, the market size reached USD 478 million, an increase of 15.46%^[2]。

Member of the Communist Party of China, national model worker, top ten health guards in the capital, founder, first director and honorary director of Peking University Liver Disease Research Institute, former director of laboratory department and hepatitis department of Peking University People's Hospital, doctoral supervisor and postdoctoral mobile station supervisor of Peking University School of Medicine (formerly Peking Medical University), the first and second vice chairmen, the third chairman and the fourth honorary chairman of Laboratory Branch of Chinese Medical Association, the first, second and third members of the editorial committee of Chinese Journal of Laboratory Medicine, the fourth editor-in-chief, the fifth honorary editor-in-chief, the sixth, seventh and eighth consultant, and Professor Tao Qimin, a famous experimental diagnosis expert, clinical immunology expert and liver disease expert in China, died in Beijing on November 15th, 2017 at the age of 86 due to ineffective treatment.